1Audet P R , Baine N H, Benincosa L J, et al. Epristeride steroid 5α-reductase inhibitor treatment for benign prostatic hyperplasia[J]. Drugs Fut, 1994, 19(7): 646-50.
2Metcalf B W, Holt D A, Levy M A,et al. Communication:potent inhibition of human steroid 5α-reductase (Ec 1.3. 1.30) by 3-androstene-3-carboxylic acids[J]. Bioorg Chem,1989,17: 372-376.
3George F W, Johnson L, Wilson J D. The effect of a 5(-reductase inhibitor on androgen physiology in the immature male rat[J]. Endocrinology, 1989, 125: 2434-2438.
4Holt D A, Levy M A, Ladd D L, et al. Steroidal a ring aryl carboxyiic acid: a new class steroid 5a-reductase inhibitors[J]. J Med Chem, 1990,33:937-942.
5Baine N H, Owings F F, Kline D N, et al. Improved syntheses of epristeride, a potent human 5a-reductase inhibitor[J]. J Org Chem, 1994,59:5987-5989.
7Geller J, Sionit L. Basic studies and clinical experience with finasteride[J]. J Endocrinol Invest, 1994, 17 (suppl 1-3):15.
8Lanb J C, Levy M A, Johnson R K, et al. Response of rat and human prostatic cancers to the novel 5A-reductase inhibitor, SK＆F 105657[J]. The Prostate, 1992, 21: 15-34.
9Levy M A, Brandt M, Sheedy K M, et al. Interaction between rat prostatic steroid 5a-reductase and 3-carboxy- 17β-substituted steroids: novel mechanism of enzyme inhibition[J]. J Steroid Biochem, 1989, 34(1-6): 571-575.
10Levy M A, Brandt M, Sheedy K M, et al. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5(-reductase isoform 2[J]. d Steroid Biochem. Molec Biol. 1994, 489(2-3): 197-206.
